⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DSGN News
Design Therapeutics, Inc. Common Stock
Diagonal Therapeutics Appoints Industry Veteran Jeremy Bender, Ph.D., M.B.A., as Chair of the Board of Directors
globenewswire.com
DSGN
GILD
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
globenewswire.com
DSGN
Form 8-K
sec.gov
DSGN
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
globenewswire.com
DSGN
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
globenewswire.com
DSGN
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
globenewswire.com
DSGN
Form 8-K
sec.gov
DSGN
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
globenewswire.com
DSGN
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
globenewswire.com
ANAB
DSGN
Form 8-K
sec.gov
DSGN